197 related articles for article (PubMed ID: 30668713)
1. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy.
Frasca K; Morrow M; Coyle RP; Coleman SS; Ellison L; Bushman LR; Kiser JJ; Zheng JH; Mawhinney S; Anderson PL; Castillo-Mancilla J
J Antimicrob Chemother; 2019 May; 74(5):1395-1401. PubMed ID: 30668713
[TBL] [Abstract][Full Text] [Related]
2. Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence.
Morrow M; MaWhinney S; Coyle RP; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR
AIDS; 2021 Oct; 35(12):1949-1956. PubMed ID: 34127580
[TBL] [Abstract][Full Text] [Related]
3. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
[TBL] [Abstract][Full Text] [Related]
4. Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV.
Castillo-Mancilla JR; Coyle RP; Coleman SS; Morrow M; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL
AIDS Res Hum Retroviruses; 2020 Mar; 36(3):173-175. PubMed ID: 31204866
[TBL] [Abstract][Full Text] [Related]
5. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV.
Yager JL; Coyle RP; Coleman SS; Ellison L; Zheng JH; Bushman L; Gardner EM; Morrow M; MaWhinney S; Anderson PL; Justice Kiser J; Castillo-Mancilla JR
J Int Assoc Provid AIDS Care; 2019; 18():2325958219888457. PubMed ID: 31750768
[TBL] [Abstract][Full Text] [Related]
6. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).
Coyle RP; Morrow M; Mann SC; Mainella V; Ellis SL; Schwab S; Coppinger C; Barker N; Ellison L; Zheng JH; Al Zuabi S; Alpert PE; Carnes TC; Buffkin DE; Chai PR; Bushman LR; Kiser JJ; MaWhinney S; Brooks KM; Anderson PL; Castillo-Mancilla JR
Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38636950
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
Spinelli MA; Glidden DV; Anderson PL; Gandhi M; Cohen S; Vittinghoff E; Coleman ME; Scott H; Bacon O; Elion R; Kolber MA; Buchbinder SP; Liu AY
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):158-162. PubMed ID: 31095005
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
Castillo-Mancilla JR; Morrow M; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL
Clin Infect Dis; 2019 Apr; 68(8):1335-1342. PubMed ID: 30137238
[TBL] [Abstract][Full Text] [Related]
10. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.
Gandhi M; Glidden DV; Liu A; Anderson PL; Horng H; Defechereux P; Guanira JV; Grinsztejn B; Chariyalertsak S; Bekker LG; Grant RM;
J Infect Dis; 2015 Nov; 212(9):1402-6. PubMed ID: 25895984
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD
J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.
Morrow M; MaWhinney S; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR
J Infect Dis; 2019 Jul; 220(4):635-642. PubMed ID: 30942881
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.
Farmer A; Wang X; Ganesan A; Deiss RG; Agan BK; O'Bryan TA; Akers K; Okulicz JF
AIDS Res Ther; 2016; 13():16. PubMed ID: 27006682
[TBL] [Abstract][Full Text] [Related]
16. Urine point-of-care tenofovir test demonstrates strong predictive clinical and research utility.
Mustanski B; Ryan DT; Spinelli MA; Gandhi M; Newcomb ME
AIDS; 2023 Dec; 37(15):2381-2387. PubMed ID: 37696260
[TBL] [Abstract][Full Text] [Related]
17. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
[TBL] [Abstract][Full Text] [Related]
18. Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.
Schauer AP; Sykes C; Cottrell ML; Prince H; Kashuba ADM
J Pharm Biomed Anal; 2018 Feb; 149():40-45. PubMed ID: 29100029
[TBL] [Abstract][Full Text] [Related]
19. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS.
Waitt C; Diliiy Penchala S; Olagunju A; Amara A; Else L; Lamorde M; Khoo S
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():300-307. PubMed ID: 28651173
[TBL] [Abstract][Full Text] [Related]
20. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
